Library > Country Reports



With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies…

Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European…

Switzerland, long held up as an innovation powerhouse able to hold its own against the considerably larger neighbouring life science markets of France and Germany, has, in some respects, found the going tougher of late. The country’s domestic drug market has been enduring…

A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This…

The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US…

HCLS Review USA Data is an extensive compilation of data and infographics from the world’s largest and most important pharmaceutical market. US sales of drugs accounted for 48 percent of the global market for pharmaceuticals in 2019 and pharma market spending is on the…

HCLS Review Middle East & North Africa Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharmaceutical industries, and R&D in some of the region’s most dynamic markets. This new 51-page report contains data…

HCLS Review Asia-Pacific Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharmaceutical industries, and R&D in some of the region’s most dynamic markets. This new 38-page report contains data from Australia,…

This exclusive new report examines how Belgium has been able to establish itself as the ‘Pharma Valley of Europe’, famed for the quality and breadth of its medical research, the scale and complexity of its manufacturing infrastructure, and its multilingual, highly…

HCLS Review Europe Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharma markets, and R&D across Europe. This new 95-page report contains data from 17 different countries and is an invaluable resource for anyone…

Somewhat of a bastion of openness, predictability, and stability in a region often mired with turmoil, volatility, and economic nationalism, Morocco is increasingly attracting the attention of international investors across a range of industries. Nowhere is this more…

Following a battering by the 2008 global financial crisis and the austerity policies the country was forced to implement, Romania’s economy has rebounded well over the past few years, allowing the oft-overlooked Eastern European country to top the European Union table with…

We use cookies to ensure that we give you the best experience on our site. For more info click here